Replies to post #197044 on Biotech Values

[DewDiligence]

… [levodopa] works for delaying onset of dry AMD and slowing the progression of dry to wet. Is that your reading too?

Here’s an expanded version of the same PR:

http://www.brightfocus.org/macular/news/brightfocus-supported-researchers-show-link-between-parkinsons-drug-and-curbing-macular-degeneration

…researchers first examined the health records of 37,000 patients at the Marshfield Clinic, comparing outcomes among patients who had AMD, or were taking L-DOPA for Parkinson’s or another condition, or both. These researchers found that among people who got L-DOPA before being diagnosed with AMD, their AMD diagnosis occurred eight years later than those not taking L-DOPA. These provocative findings were then confirmed in a much larger data set of 87 million patients, where similar results were observed.

Next, the study was expanded to investigate the association between L-DOPA use and prevention and delay of “wet” AMD… And once again, L-DOPA was found to be protective.

I would say this is a plausible hypothesis, but it ought to be tested in a prospective study. The question is: Who will conduct such a study?